During ASCO 2016, 190 abstracts were presented in the lung cancer track: 18 oral presentations, 22 discussion sessions and 172 posters. This report will highlight 7 selected phase III trials and 3 small but promising phase I/II trials.
This year’s ASCO focused on the promising and exciting domain of immunotherapy with checkpoint inhibitors. Of special interest were the data in first line treatment of NSCLC, the combination of PD-L1 and CTLA-4 antibodies, and the phase I/II results in mesothelioma, small cell lung cancer and thymic carcinoma.
Other highlights of ASCO 2016 in the field of thoracic oncology included updated results of new targeted therapies for patients with defined molecular targets and for patients with acquired resistance after firstgeneration EGFR or ALK-inhibitors.

(BELG J MED ONCOL 2016;10(5):179–185)